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Comparative effectiveness research became the focal point of
high expectations in 2010 when it was given a starring role in
the health care reform bill passed by the U.S. Congress. The
goal of comparative effectiveness research from a policy per-
spective is intuitively very appealing: to identify what works
based on evidence to guide the provision of high-quality
clinical care. In this modern re-envisioning of medicine, the
“evidence” produced by comparative effectiveness research is
the engine that powers clinical management and comprises
both clinical trial results and high-quality observational re-
search. These data are aggregated into meta-analyses and
systematic reviews and are used to inform clinical practice
guidelines. What rarely gets mentioned, however, is the critical
operational next step in the process: translating the published
evidence and guideline recommendations into shared treat-
ment decisions for individual patients.
See page 1557
Traditionally, when the acute risk of death is high, preven-
tion of death tends to dominate treatment decisions. Major
disabling stroke is one of the few nonfatal endpoints that
patients rank equal to or more important than death in making
treatment choices. Moving from acute to chronic disease
management decision making means that as the risks of death
and major disabling morbidity go down, the other unintended
consequences of each therapeutic option become quantitatively
more important in decision making. In addition, the nature of
the evidence supporting treatment alternatives changes. As-
suming common sample sizes and hypothesized relative ben-
efits, clinical trials studying what works in lower risk cohorts
have less statistical power to work with and often use compos-
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Two strong assumptions underlie the use of the most common
form of composite endpoint (reflecting treatment efficacy):
first, that the components are all equally important to patients,
and second, that the individual components all reflect the same
relative therapeutic effect (1). In other words, the components
are reasonable surrogates for each other. Recently, however, a
second form of composite endpoint has been increasingly used
in interventional cardiology, in which adverse effects related to
both efficacy and safety of each of the treatments being
compared are combined into a metric reflecting total net
morbidity/mortality. This “net benefits–harms” type of end-
point has also been incorporated into the most recent trials
comparing revascularization options for carotid artery disease,
yet the result to date has been more controversy than clarity.
The evolution of treatment for carotid atherosclerotic
arterial disease has a number of interesting parallels with
coronary artery disease. In both cases, the genesis of our
modern understanding of the disease can be traced back
some 60 years. The first carotid endarterectomy (CEA) was
described in 1953, substantially ahead of the first coronary
artery bypass procedures more than a decade later, and the
first carotid stents were used clinically in 1994, the same year
the Food and Drug Administration approved the Palmaz-
Schatz stent for coronary artery use. However, unlike coronary
artery disease, the increasing degree of carotid atherosclerosis
has been linked to the probability of future strokes. In addition,
both CEA and carotid artery stenting (CAS) tend to accom-
plish similar degrees of revascularization. Two clinical trials
established CEA as being superior to the medical therapy of
the 1990s for symptomatic patients with stenosis70%. Three
additional trials reported between 1993 and 2004 provided
evidence for improved outcomes with CEA over medical
therapy alone in asymptomatic subjects with 60% stenosis,
although the magnitude of benefit was considerably smaller.
As with percutaneous coronary intervention, develop-
ment of percutaneous carotid revascularization was stimu-
lated by the potential for providing a less invasive, potentially
safer alternative to operation. Numerous meta-analyses have
been performed over the last 5 years on the growing
evidence base of randomized trials comparing carotid stent-
ing with CEA, but they have failed to reach a clear
consensus on how patients should be treated (2–4). At the
same time, data show that carotid stent use is growing while
use of CEA is flat or even falling modestly (5).
Examination of the most recent trial of CEA versus
stenting helps to illustrate why more trial data are not likely
to resolve the current controversies about treatment superi-
ority. The North American CREST (Carotid Revascular-
ization Endarterectomy Versus Stenting Trial) study found
that, in average risk subjects, almost one-half of whom were
considered asymptomatic with no preceding transient isch-
emic attack or stroke symptoms related to the target artery,
the composite primary endpoint (stroke, myocardial infarc-
tion [MI], or death in the perioperative period and ipsilat-
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median follow-up of 2.5 years (hazard ratio for stenting
1.11, p  0.51) (6). This would suggest that the choice of
revascularization procedure is a toss-up. Kassirer and Pauker
(7) defined “toss-ups” as “clinical situations in which the
consequences of divergent choices are, on the average,
virtually identical.” However, the path to equivalence was
not symmetrical in the 2 arms of the CREST study. In the
periprocedural period, stent arm patients had 4 per 1,000
more deaths (p  0.18), 18 per 1,000 more strokes (pre-
dominantly but not exclusively “minor” or “nondisabling”
[p  0.01]), 11 per 1,000 fewer MIs (a mix of clinically
evident and biomarker-only events [p  0.03]), and 44 per
,000 fewer cranial nerve palsies (not included in primary
ndpoint [p  0.05]). Both the clinical and the biomarker-
nly MIs confer an adverse long-term prognosis (8). After
he periprocedural period, the rates of ipsilateral stroke were
quivalent in the 2 arms out to 4 years (2.0% for stenting vs.
.4% for CEA, p  0.85).
Surprisingly few of the clinical trials of stenting versus
EA before the CREST study assessed patient-reported
utcomes, specifically health-related quality of life (QOL).
he preference among trialists for objective, event-type
utcomes is not unique to carotid revascularization trials (9).
owever, as the difference between treatments in rates of
ajor morbid outcomes gets smaller and smaller, the
mportance of understanding the patient’s experience of the
ifferent treatments becomes greater. Can health-related
OL information provide the clarity that equally weighted
omposite endpoints have failed to generate? Using the
edical Outcomes Study Short Form-36 health status
ssessment, the CREST study investigators found that a
ajor stroke was about 3 times worse in its effect on QOL
han a minor stroke was, whereas an endpoint MI had about
wo-thirds the QOL effect of a minor stroke (6).
In this issue of the Journal, Cohen et al. (10) report
additional details from the QOL portion of the CREST
study. Their study reported 2 important findings. First, the
major differences in QOL between CAS and CEA occurred
early and were related to the recovery after the procedures.
No differences were seen at 12 months. Second, an endpoint
stroke had large adverse effects on 1-year QOL, particularly
in the areas of physical function, role functioning, and
vitality (energy/fatigue). In contrast, endpoint MI and
cranial nerve palsies had quantitatively smaller, and not
statistically significant, effects on QOL. At first glance, the
2 findings of this study might seem at odds. If strokes cause
persistent decrements in QOL whereas MI and cranial
nerve palsies do not, should not the QOL scores for the
stent arm reflect this? The resolution is found by focusing
on the absolute number of excess perioperative strokes
caused by stenting: 18 per 1,000. Even assuming that all 18
had a major disabling stroke (in contrast to the CREST
study data, which showed that most of the strokes were not
disabling), such a small number has an imperceptible effecton the population mean QOL values. Thus, our evaluation
of the QOL data supports the view of the choice between
stenting and CEA as a toss-up.
Finding that the choice between these 2 therapeutic
options is a toss-up considering both clinical and QOL
outcomes means primarily that, for the clinician, whose
primary role is to provide expert advice to the patient, there
is no “wrong decision.” That can be particularly difficult to
convey to patients who want the “best therapy,” and it is
important to recognize that we should not be asking
patients to choose whether they would rather face a slightly
higher risk of having a stroke or an MI and pick their
treatment on that basis. Neither risk can be completely
avoided as both events occur after each procedure, but the
incremental risks are too low to affect the expected QOL
results of either treatment. Patients may still not be indif-
ferent to the choice of therapy, due to preferences for the
less invasive nature of stenting with less pain and a shorter
hospital stay or concerns regarding unresolved questions
about the long-term cognitive effects of microembolic
events during stenting, even with protection devices (11).
And payers may not be indifferent to the modestly higher
costs of stenting (12). In the end, patients need a balanced
presentation of risks and benefits framed in a neutral way.
Knowledge of local experience (procedure volumes and
complication rates) can be particularly helpful, but accurate
data are often difficult to obtain and to interpret properly.
The largest area of uncertainty in the contemporary
management of significant carotid disease is actually not
which revascularization procedure to select but whether
patients who are asymptomatic need revascularization at all.
Such patients comprise 50% of current carotid revascular-
ization procedures each year, and the modest outcome
benefits seen previously in this cohort may have been
eliminated by interval advances in medical therapy (13).
Given that new comparative effectiveness evidence will
likely continue to employ various forms of composite
clinical endpoint variables for efficiency purposes, also in-
cluding the patient’s perspective in the form of patient-
reported outcomes will be crucial in being prepared to take
that next step: translating evidence into practice.
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